Abstract: Objective To systematically evaluate the propofol pharmacokinetics of patients with hepatosis. Methods Trials were located through electronic searches of the MEDLINE （1975.01-2010.10）, OVID, Springerlink, CNKI （1979-2010.10）, VIP （1989-2010.10）, WANFANG data base （1996-2010.10）, CBM （1978-2010.10）, to collect the randomized controlled trials （RCTs） and clinical controlled trials （CCTs） about propofol pharmacokinetics, supplemented by manual retrieval. The methodological quality of included trials was assessed, while the data were extracted and evaluated by two reviewers independently according to the Cochrane Handbook. The Revman 4.2 software was used for meta-analysis. Results A total of six trials were included. Meta analysis showed: the central volume distribution and clearance of propofol in patients with hepatosis were similar to those without hepatic dysfunction. There were no differences in half lives of propofol between two groups,and for the constant rates there were no differences, either. Compared with the control group, patients with hepatosis could significantly increase the steady-state distributions WMD=1.24, 95%CI（0.38, 2.10）, P=0.005. Conclusions The pharmacokinetics of propofol in patients with hepatosis were similar to the people without hepatic dysfunction. Patients with hepatosis couldn’t reduce propofol dosage. The conclusion still needs high quality clinical control trials to verify.